ELVN-001 Shows 69% Response Rate in CML Phase 1b Trial Results

Enliven Therapeutics (ELVN) reports encouraging Phase 1b results for ELVN-001, a new treatment for chronic myeloid leukemia, with strong response rates and excellent safety profile.